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Abstract
Diundecyl phthalate (DUP) is a high production volume chemical used as a plasticizer in 
polyvinyl chloride and other plastics. Specific biomarkers of DUP would be useful for human 
exposure assessment. To identify such biomarkers, we investigated the in vitro metabolism of DUP 
with human liver microsomes using online solid phase extraction coupled to HPLC-mass 
spectrometry. Using high resolution mass spectrometry, we conclusively confirmed the structures 
of four DUP specific metabolites: mono-undecyl phthalate (MUP), mono-hydroxyundecyl 
phthalate (MHUP), mono-oxoundecyl phthalate (MOUP), and mono-carboxydecyl phthalate 
(MCDP). We also used high resolution mass spectrometry to isolate MCDP and MHUP from co-
eluting isobaric metabolites of diisononyl phthalate (i.e., mono-carboxyisononyl phthalate) and 
diisododecyl phthalate (i.e., monohydroxyisododecyl phthalate), respectively, that could not be 
separated with low resolution tandem mass spectrometry. To evaluate the potential usefulness of 
the newly identified DUP metabolites as exposure biomarkers, we analyzed 36 human urine 
samples by high resolution mass spectrometry. We detected MHUP and MCDP in > 83% of the 
samples; median concentrations were 0.21 ng/mL and 0.36 ng/mL, respectively. MOUP was 
detected only in 14% of the samples analyzed, and MUP was not detected. All three metabolites 
eluted as peak clusters likely because of the presence of multiple oxidation sites and multiple 
isomers in DUP technical mixtures. Taken together, these findings suggest that with the 
appropriate mass spectrometry quantification techniques, MHUP and MCDP may serve as suitable 
biomarkers for assessing background exposure to DUP.
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Diundecyl phthalate (DUP, Palatinol®111P-1, Jayflex™ L11P-E), a high molecular weight 
phthalate comprised of a pair of 11-carbon esters linked to a benzene-1,2-dicarboxylic 
moiety, is manufactured as a mixture of primarily branched chain isomers. DUP is a high 
production volume chemical (OECD, 2015) mainly used as a polyvinyl chloride (PVC) 
plasticizer in applications requiring low fog and low temperature flexibility such as wiring, 
cable jacketing and insulation, furniture and automobile upholstery, and flooring and wall 
covering (NICNAS, 2008; US Consumer Product Safety Commission, 2010). DUP can also 
be used in non-PVC polymers; in flame retardant nylon, rubbers, paints, and adhesives 
(NICNAS, 2008; US Consumer Product Safety Commission, 2010). US production of DUP 
and its proportion in the total phthalate production market have been slowly increasing since 
the implementation of chemical tracking in 1982 (US Consumer Product Safety 
Commission, 2010).
Toxicity data for DUP are relatively limited (Barber et al., 2000; David et al., 2001; Kwack 
et al., 2009, 2010; Saillenfait et al., 2013). Exposure to C7-11 phthalate monoester mixture 
did not show mutagenic potential in the L5178Y mouse lymphoma mammalian cell 
mutation assay, or genotoxicity in the Balb/3T3 cell transformation assay (Barber et al., 
2000). In another in vitro study, cell-to-cell communication was inhibited by the C7-C11 
phthalate monoester mixture with rat and mouse hepatocytes, but not with hamster, 
cynomolgus monkey, or human hepatocytes or in a human liver cell line; the same C7-11 
monoester mixture did not markedly change peroxisomal beta-oxidation in hepatocytes from 
any species (Kamendulis et al., 2002). Exposure to DUP (500 mg/kg body weight/day) for 4 
weeks in Sprague-Dawley male rats decreased sperm count and sperm mobility, although it 
did not significantly affect liver or testis weights (Kwack et al., 2009). In another study, male 
Sprague-Dawley rats administered 500 mg/kg body weight/day of DUP for two weeks 
showed significant increases in aspartate aminotransferase and alkaline phosphatase (Kwack 
et al., 2010). In Sprague-Dawley rats dosed with 0.5 and 1 g DUP/kg body weight/day by 
gavage on gestation days 6–20, maternal body weight and food consumption were not 
affected, but, compared to controls, treated fetuses showed small decreases in anogenital 
distance (males) as well as a higher incidence of supernumerary lumbar ribs (Saillenfait et 
al., 2013). Although health effects of DUP in humans are largely unknown, identifying 
biomarkers of DUP would facilitate human exposure assessment, particularly because 
exposures to phthalates and phthalate alternatives may be changing as a result, at least in 
part, of legislative activity, industrial practices, public concerns and consumers' demands 
(Goen et al., 2011; Health Canada 2013; Schutze et al., 2014; Silva et al., 2013; Wittassek et 
al., 2007; Zota et al., 2014).
In vitro metabolism has been used to identify potential bio-markers of exposure to select 
environmental chemicals (Choi et al., 2013; Roberts et al., 2012; Silva et al., 2015). For the 
current study, we used high resolution mass spectrometry to conclusively identify potential 
DUP specific exposure biomarkers after in vitro metabolism of DUP using human liver 
microsomes. We also quantified the urinary concentrations of these DUP metabolites in 36 
samples collected in 2013–2015 from a convenience sample of adults with no known 
occupational exposure to DUP.
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2. Materials and methods
2.1. Reagents and standards
DUP ( > 99%, CAS # 3648-20-2) and acetic acid were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). 4-methyl-7-oxo-octyl phthalate (MONP), 4-methyl-7-hydroxyoctyl 
phthalate (MHNP), 4-methyl-carboxyheptyl phthalate (MCOP), d4-MONP, d4-MHNP 
and 13C6-MCOP were purchased from ADM (Teltow, Germany). β-glucuronidase 
(Escherichia coli-K12) was purchased from Roche Biomedical (Mannheim, Germany). 
Acetonitrile (HPLC grade) was purchased from Burdick and Jackson (VWR, Radnor, PA). 
All reagents, solvents and standard materials were used without further purification.
2.2. Urine collection
We used 36 spot urine specimens collected anonymously from U.S. adult volunteers in 
Atlanta, GA in 2013–2015, and stored at −70 °C until analysis. The volunteers had no 
documented occupational exposure to DUP. CDC's Subjects Institutional Review Board 
reviewed and approved the collection of the samples. A waiver of informed consent was 
requested under 45 CFR 46.116(d); no personal or demographic data were available.
We also used archived urine, stored at −70 °C until analysis, that had been collected from 
rats dosed with diisodecyl phthalate (DiDP) (500 mg/kg body weight) as presented 
elsewhere (Kato et al., 2007).
2.3. In vitro metabolism of DUP
We followed a procedure similar to the approach described previously (Choi et al., 2013; 
Roberts et al., 2012; Silva et al., 2015). In a 30 mL Qorpak™ Clear Wide Mouth French 
square bottle (Fisher Scientific, Pittsburg, PA, USA), DUP standard solution (1 mL, 1.3 
mg/mL) was concentrated to approximately 0.5 mL under a stream of nitrogen. Then, we 
added pH 7.4 phosphate buffer (0.1 M, 8 mL), water (1 mL), NADPH solution (A) (500 μL, 
BD Gentest™, Woburn, MA, USA), NADPH solution (B) (100 μL, BD Gentest™) to 
generate NADPH in situ using an enzymatic reaction, and female pooled human liver 
microsomes (200 μL, BD Gentest™). The bottle was capped and the contents were gently 
mixed and placed in an incubator (Fisher Scientific, Hampton, NH, USA) at 37 °C for 8 h. 
Because of the limited water solubility of DUP and to produce in vitro metabolites in 
sufficient amounts for mass spectrometry identification, after 8 h, the solution was 
replenished with 500 μL NADPH solution (A), 100 μL NADPH solution (B), and 200 μL 
female human liver microsomes, gently mixed, and in-cubated for another 17 h. Aliquots of 
microsomal suspension (1 mL) were transferred into microcentrifuge tubes, vortex mixed, 
and centrifuged at 12,500 rpm for 20 min on an Avanti high performance centrifuge 
(Beckman Coulter Inc, Brea, CA, USA). The supernatant was transferred into autosampler 
vials for analysis (Silva et al., 2015). The above procedure was repeated without DUP, but 
with water (500 μL) for the preparation of the control samples.
2.4. Identification of in vivo and in vitro DUP metabolites
The HPLC gradient for separation of DUP metabolites and the on-line solid phase extraction 
(SPE) procedure were adapted from methods published elsewhere (Silva et al., 2007). 
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Briefly, in vitro metabolites in the supernatant of the human liver microsomal homogenate 
(500 μL) obtained after incubating with DUP were extracted using on-line SPE on a 
Chromolith RP-18 pre-column (Merck KGaA, Darmstadt, Germany) and resolved on a 
Betasil phenyl HPLC column (3 μM, 2.1 mm × 25 mm, ThermoFisher Scientific, San Jose, 
CA, USA) using a water/acetonitrile gradient. The mass spectral analysis was initially 
performed on a TSQ Vantage AM triple quadrupole mass spectrometer (ThermoFisher 
Scientific, San Jose, CA, USA). All ions on Q1 were scanned from m/z = 150 to m/z = 480 
in electrospray ionization (ESI)-negative ion mode. ESI Q1 full scan produced multiple 
peaks at m/z of 319, 333, 335 and 349. For in vivo metabolite identification, human and rat 
urine (1 mL) were treated with β-glucuronidase before separation and detection of the DUP 
biomarkers (Silva et al., 2007). The identity of the DUP metabolites was confirmed by high 
resolution mass spectrometry using parallel reaction monitoring (PRM) on a QEx-active 
Plus mass spectrometer (ThermoFisher Scientific, San Jose, CA, USA) in negative mode to 
obtain accurate m/z of precursors without applying collision energy [CE] and products of the 
DUP metabolites after applying CE (Table 1).
2.5. Quantification of DUP metabolites in human urine
After vortex mixing and aliquoting, human urine (100 μL) was spiked with the internal 
standard solution containing d4-MHNP, d4-MONP, and 13C6-MCOP. The target metabolites 
were extracted after hydrolysis with β–glucuronidase, chromatographically resolved by 
HPLC, and detected by high resolution mass spectrometry in PRM mode after applying CE 
(Table 1). The mobile phases were 0.1% acetic acid in water and 0.1% acetic acid in 
acetonitrile. The DUP metabolites were quantified using the calibration curves derived from 
analogous metabolites of di-isononyl phthalate (DiNP), namely MHNP, MONP, and MCOP. 
The limits of detection (LOD) of all analytes were set at the lowest standard concentration 
(0.01 ng/mL).
3. Results and discussion
The metabolism of high molecular weight phthalates, such as DUP, generally involves the 
formation of hydrolytic monoesters, followed by oxidation (Phase I reaction) and/or 
conjugation (Phase II reaction) before urinary excretion. These metabolites, in turn, can 
serve as biomarkers of exposure to the parent phthalate (Silva et al., 2013). We undertook 
the current study to identify and characterize in vitro and in vivo exposure biomarkers of 
DUP.
Full scan mass spectra in negative ion mode from m/z = 150 to m/z = 480 of the supernatant 
of the human liver microsomes incubated with DUP revealed four unique peaks with m/z = 
319, 333, 335 and 349. We did not observe these peaks in the microsomal suspension when 
incubated without DUP suggesting that the m/z = 319, 333, 335 and 349 peaks corresponded 
to in vitro metabolites of DUP. First, we analyzed fragmentation patterns through product 
ion scans and tentatively identified the m/z specific for three oxidative (m/z = 333, 335, 349) 
and one hydrolytic (m/z = 319) DUP metabolites. Then, we determined the accurate masses 
of these metabolites and their mass fragments by high resolution mass spectrometry and 
conclusively identified the metabolites as monoundecyl phthalate (MUP, m/z = 319.1915, 
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Fig. 1S), mono-oxoundecyl phthalate (MOUP, m/z = 333.17075, Fig. 1), mono-
hydroxyundecyl phthalate (MHUP, m/z = 335.18640, Fig. 2), and mono-carboxydecyl 
phthalate (MCDP, m/z = 349.16566, Fig. 3). Interestingly, for the in vitro study we used 
reagent grade DUP, and MOUP and MHUP eluted as peak clusters most likely because 
oxidation occurred at different carbons on the C11 side chain. By contrast, because MCDP 
can only result from ω-oxidation in the side chain, the fact that MCDP eluted as three 
distinct peaks suggests that the DUP used for the in vitro study also contained branched 
isomers (Fig. 4). Similarly, we observed three closely eluting MUP peaks (Fig. 4).
We also detected these metabolites in human urine (Fig. 4). Both in vivo and in vitro 
metabolites produced similar mass fragments (Figs. 1–3, S1). However, in vitro metabolites 
resulting from incubation of DUP retained longer on the HPLC column than the in vivo 
metabolites present in the human urine (Fig. 4), perhaps reflecting differences in metabolite 
structures (e.g., fraction of branched vs. linear isomers). Using the same analytical method, 
we evaluated the elution of DUP metabolites in archived urine samples from rats dosed with 
a commercial DiDP, a product that also contained branched DUP isomers (European 
Chemicals Bureau, 2003). The DUP metabolites in the rat urine eluted at similar retention 
times and with similar peak shape as the DUP metabolites detected in human urine. Of 
interest, in both human and rat urine, MCDP eluted as a abroad peak cluster suggesting that 
the DUP used in commercial products contains mainly branched iso-mers with numerous 
potential ω-oxidation sites.
To study environmental exposure of DUP, we measured four DUP metabolites in 36 spot 
urine samples collected from a convenience sample of adults with no known occupational 
exposure to DUP using online SPE coupled with HPLC and high resolution mass 
spectrometry. We detected MHUP (86%) and MCDP (83%) in most samples, whereas 
MOUP was detected only in 14% of the samples tested (Table 2). MHUP and MCDP were 
also detected at higher concentrations than MOUP (Table 2). Because MUP is relatively 
hydrophobic and would be further metabolized before its excretion in urine, MUP was not 
detected. As expected, the urinary concentrations of MHUP correlated well with MCDP (p < 
0.001). Because high resolution mass selection excludes most isobaric chemical 
interferences (Be et al., 2013), we achieved well defined chromatographic peak clusters even 
at concentrations below the LOD of 0.01 ng/mL.
Simultaneous exposure to DiDP (C10 side chain), DUP, and diisododecyl phthalate (DiDoP, 
C12 side chain) in humans would produce urinary metabolites isobaric to some DUP 
metabolites [e.g., MHUP (m/z = 335.186) and monocarboxynonyl phthalate (MCNP, m/z = 
335.150); and MCDP (m/z = 349.166) and mono-hydroxydodecyl phthalate (MHDoP, m/z = 
349.202)] (Fig. 5). Because all of these metabolites have similar chemical characteristics and 
elute as peak clusters, full chromatographic separation is difficult to achieve (Fig. 5). 
However, high resolution mass spectrometry adequately separated DUP metabolites in the 
presence of isobaric DiDP and DiDoP metabolites. We observed a higher contribution from 
the isobaric DiDP metabolite (MCNP) to MHUP than of the isobaric DiDoP metabolite 
(MHDoP) to MCDP, perhaps because human exposure to DiDP is higher than the exposure 
to DiDoP. Because the relative abundance of the specific fragments is different in isobars, 
when using low resolution tandem mass spectrometry for quantifying MHUP and MCDP, 
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isobaric interferences can be minimized by selecting appropriate fragment (s) for product 
ion scan.
In summary, we identified four DUP specific in vitro metabolites, MUP, MHUP, MOUP, and 
MCDP. Our data also suggest that MHUP and MCDP could serve as suitable biomarkers for 
assessing DUP exposure in humans. High resolution mass spectrometry would provide the 
best choice for quantification, due to low LOD and because these metabolites may partially 
co-elute with isobaric metabolites of DiDP or DiDoP. Therefore, if using the more common 
low resolution tandem mass spectrometry biomonitoring approach to detect DUP 
biomarkers, attention should be given to achieve adequate chromatographic separation to 
remove isobaric interferences or to select appropriate fragments to distinguish co-eluting 
isobaric metabolites from DiDP and DiDoP.
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High resolution mass spectrometric fragmentation of mono-oxoundecyl phthalate identified 
in human liver microsomes (HLM) after in vitro metabolism of DUP (top) and in human 
urine (bottom).
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High resolution mass spectrometric fragmentation of monohydroxyundecyl phthalate 
identified in human liver microsome (HLM) homogenate after in vitro metabolism of DUP 
(top) and in human urine (bottom). Different ratios of fragments resulted due to structural 
differences in isomers of DUP used in in vitro study (mainly linear) and in commercial 
formulations (mainly branched).
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High resolution mass spectrometric fragmentation of monocarboxydecyl phthalate identified 
in human liver microsomes (HLM) after in vitro metabolism of DUP (top) and in human 
urine (bottom).
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Chromatographic separation of DUP metabolites detected in human liver microsomal 
(HLM) suspension after incubation with DUP, in human urine, and in DiDP dosed rat urine.
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Interfering isobars MCNP (m/z = 335) and MHDoP (m/z = 349), from the metabolites of 
DiDP and DDoP to DUP metabolites, MHUP (m/z = 335) and MCDP(m/z = 349).
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Table 1
QExactive high resolution mass spectrometric parameters for measuring the metabolites of diundecyl 
phthalate.
DUP metabolite m/z NCE*
Precursor Product
Mono-oxoundecyl phthalate (MOUP) 333.1708 121.030 29
Mono-hydroxyundecyl phthalate (MHUP) 335.1864 187.170 25
Mono-carboxydecyl phthalate (MCDP) 349.1657 201.150 12
The structure shown is for one isomer only.
*
NCE–normalized collision energy
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Table 2
Urinary concentrations of diundecyl phthalate metabolites in a convenience sample of US adults
a
 (N=36).
Percentile Urinary diundecyl phthalate metabolite concentrations
b
, ng/mL
MUP MOUP MHUP MCDP
50th <LODc <LODc 0.21 0.36
75th <LODc <LODc 0.64 0.67
90th <LODc 0.20 13.7 11.5
95th <LODc 0.48 29.2 12.8
a
Spot urine samples were collected in 2013–2015 from a group of US adults with no known occupational exposure to DUP.
b
Estimated concentrations based on the calibration curves of DiNP metabolite analogs
c
LOD=0.01 ng/mL
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